Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2022, Vol. 51 Issue (5): 626-633    DOI: 10.3724/zdxbyxb-2022-0075
细胞因子     
细胞因子类药物在眼科临床的应用进展
王晓杰,惠琦,金子,饶凤琴,余丙洁,靳磊,BANDA Joshua,李校堃
温州医科大学药学院，浙江 温州 325035
Progress on the application of growth factor-related drugs in ophthalmology
WANG Xiaojie,HUI Qi,JIN Zi,RAO Fengqin,YU Bingjie,JIN Lei,BANDA Joshua,LI Xiaokun
School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China
 全文: PDF(567 KB)   HTML( 5 )
摘要：

血管内皮生长因子、成纤维细胞生长因子、神经生长因子、表皮生长因子、干扰素等细胞生长因子是调控细胞增殖、分化和再生的重要内源性蛋白。以上述生长因子等为靶点开发的生物药物，在老年性黄斑变性、角膜损伤、神经营养性角膜炎等眼部疾病的治疗中发挥了重要作用，相应药物陆续上市。抗血管内皮生长因子类药物可以控制血管内皮的增生，减轻视网膜组织的水肿和渗出，已经成为老年性黄斑变性和糖尿病视网膜病的主要治疗手段。碱性成纤维细胞生长因子可促进角膜上皮细胞的增殖、分化和迁移，具有加速角膜损伤愈合，降低角膜炎症反应的作用，其中牛碱性成纤维细胞生长因子已用于角膜损伤临床治疗。神经生长因子能促进中枢和外周神经元的生长、发育和分化，加快神经损伤的修复，用于神经营养性角膜炎的治疗，可促进角膜完全愈合。临床上，表皮生长因子衍生物滴眼液可用于角膜上皮损伤的治疗，重组人干扰素可用于眼部病毒性感染疾病的治疗。本文就细胞因子类药物在眼科疾病治疗及新药开发的研究进展进行综述，为拓展细胞因子在眼科临床的应用提供参考。
关键词： 成纤维细胞生长因子;  血管内皮生长因子;  神经生长因子;  表皮生长因子;  干扰素;  白介素;  眼科药物;  综述    
Abstract:

Vascular endothelial growth factor（VEGF）, fibroblast growth factor（FGF）, nerve growth factor（NGF）, epidermal growth factor and interferon are important endogenous proteins that regulate cell proliferation, differentiation and regeneration. Biological products targeting growth factors are used in the treatment of ocular diseases such as wet age-related macular degeneration, corneal injury and neurotrophic keratitis. Anti-VEGF drugs can regulate the proliferation of vascular endothelia, reduce the edema and exudation of retinal tissue，which are the main therapeutic agents for wet age-related macular degeneration and diabetic retinopathy. The basic FGF (b-FGF) can promote the proliferation, differentiation, and migration of corneal epithelial cells, accelerating the healing of the corneal injury and reduces corneal inflammation；and bovine b-FGF has been approved for the treatment of corneal injuries. The NGF promotes the growth, development, and differentiation of central and peripheral neurons, thus accelerating the repair of nerve damage；and the European Medicines Agency approved the use of nerve growth factor for the treatment of neurotrophic keratitis in 2017. Recent clinical studies show that patients with moderate or severe neurotrophic keratitis achieved complete corneal healing following 8 weeks of NGF therapy. Epidermal growth factor derivative eye drops have been approved for the treatment of corneal epithelial injuries. Recombinant human interferon has been clinically used in the treatment of ocular viral infections. This article reviews the research progress in the development of new cell growth factor drugs for the treatment of ophthalmic diseases, to provide insights for expanding the application of cell growth factors in ophthalmology.
Key words: Fibroblast growth factor    Vascular endothelial growth factor    Nerve growth factor    Epidermal growth factor    Interferon    Interleukin    Ophthalmic drug    Review
收稿日期: 2022-03-01 出版日期: 2022-12-28
CLC:  R77  
基金资助: 浙江省“尖兵”“领雁”研发攻关计划（2022C03110）
通讯作者: 李校堃   
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
王晓杰
惠琦
金子
饶凤琴
余丙洁
靳磊
BANDA?Joshua
李校堃

引用本文:

王晓杰,惠琦,金子,饶凤琴,余丙洁,靳磊,BANDA Joshua,李校堃. 细胞因子类药物在眼科临床的应用进展[J]. 浙江大学学报（医学版）, 2022, 51(5): 626-633.

WANG Xiaojie,HUI Qi,JIN Zi,RAO Fengqin,YU Bingjie,JIN Lei,BANDA Joshua,LI Xiaokun. Progress on the application of growth factor-related drugs in ophthalmology. J Zhejiang Univ (Med Sci), 2022, 51(5): 626-633.

链接本文:

https://www.zjujournals.com/med/CN/10.3724/zdxbyxb-2022-0075    或    https://www.zjujournals.com/med/CN/Y2022/V51/I5/626

1 World Health Organization. World report on vision [EB/OL]. (2019-10-8) [2022-03-01]. https://www.who.int/publications/i/item/9789241516570
2 王瑞华, 贺　燚, 郝燕燕. 外伤性角膜上皮缺损的治疗——碱性成纤维细胞生长因子滴眼液的临床应用[J]. 眼外伤职业眼病杂志, 2002, 24(3): 276-277
WANG Ruihua, HE Yi, HAO Yanyan. Treatment of traumatic corneal epithelium defect[J]. Chinese Journal of Ocular Trauma and Occupational Eye Disease, 2002, 24(3): 276-277. (in Chinese)
3 梁　平, 梁　慷, 谢莉娜, 等. 贝复舒(重组bFGF)滴眼液治疗干眼症的临床研究[J]. 临床眼科杂志, 2001, 9(6): 464-466
LIANG Ping, LIANG Kang, XIE Lina, et al. A clinic study on effect of bFGF eye drops treated the patients with dry eye[J]. Journal of Clinical Ophthalmology, 2001, 9(6): 464-466. (in Chinese)
4 魏利军. 2017年美国、欧洲和日本批准的新药总结与点评(Ⅱ)[J]. 药学进展, 2018, 42(2): 148-157
WEI Lijun. Summary and review of new drugs approved by FDA, EMA and PMDA in 2017(Ⅱ)[J]. Progress in Pharmaceutical Sciences, 2018, 42(2): 148-157. (in Chinese)
5 袁鹏华. 重组人表皮生长因子衍生物滴眼剂在治疗干眼中的应用价值[J]. 中西医结合心血管病电子杂志, 2017, 5(22): 186
YUAN Penghua. Application value of recombinant human epidermal growth factor derivative eye drops in the treatment of dry eye[J]. Cardiovascular Disease Electronic Journal of Integrated Traditional Chinese and Western Medicine, 2017, 5(22): 186. (in Chinese)
6 CAMPAC. New anti-VEGF drugs in ophthalmology[J]Curr Drug Targets, 2020, 21( 12): 1194-1200.
doi: 10.2174/1389450121666200428101738
7 朱彤波. 医学免疫学[M]. 2版. 成都: 四川大学出版社, 2017: 61-76
ZHU Tongbo. Medical immunology[M]. 2nd edition. Chengdu: Sichuan University Press, 2017: 61-76. (in Chinese)
8 全国科学技术名词审定委员会. 术语在线[EB/OL]. [2022-02-20]. https://www.termonline.cn/index
China National Committee for Terms in Sciences and Technologies. Termonline[EB/OL]. [2022-02-20]. https://www.termonline.cn/index. (in Chinese)
9 李校堃, 刘　旭, 刘建华, 等. 细胞生长因子在神经康复与神经可塑性中的研究进展[J]. 中国康复理论与实践, 2022, 28(2): 175-182
LI Xiaokun, LIU Xu, LIU Jianhua, et al. Progress of cellular growth factors in neurorehabilitation and neuroplasticity[J]. Chinese Journal of Rehabilitation Theory and Practice, 2022, 28(2): 175-182. (in Chinese)
10 王　炜. 重组牛碱性成纤维细胞生长因子治疗膜性结膜炎疗效[J]. 上海医药, 2017, 38(14): 34-36
WANG Wei. Effect of recombinant bovine basic fibroblast growth factor in the treatment of membranous conjunctivitis[J]. Shanghai Medical & Pharmaceutical Journal, 2017, 38(14): 34-36. (in Chinese)
11 毕建东. 贝复舒滴眼液应用于临床治疗角膜病患者的可行性探讨[J]. 海峡药学, 2018, 30(9): 178-179
BI Jiandong. Feasibility of Beifushu eye drops in clinical treatment of patients with keratopathy[J]. Strait Pharmaceutical Journal, 2018, 30(9): 178-179. (in Chinese)
12 王　磊. 贝复舒滴眼液治疗角膜溃疡临床疗效分析[J]. 中外医疗, 2016, 35(4): 116-117
WANG Lei. Clinical curative effect analysis of bFGF eye drops in treatment of Keratohelcosis[J]. China Foreign Medical Treatment, 2016, 35(4): 116-117. (in Chinese)
13 王　爽, 苏　冉, 张前辉. 重组牛碱性成纤维细胞生长因子治疗外伤性角膜上皮缺损的临床疗效观察[J]. 四川解剖学杂志, 2020, 28(3): 177-178
WANG Shuang, SU Ran, ZHANG Qianhui. Clinical effect of recombinant bovine basic fibroblast growth factor in the treatment of traumatic corneal epithelial defect[J]. Sichuan Journal of Anatomy, 2020, 28(3): 177-178. (in Chinese)
14 赵　治, 石春和. 贝复舒(重组bFGF)滴眼液治疗干眼症的疗效观察[J]. 江苏大学学报(医学版), 2004, 14(4): 287-288
ZHAO Zhi, SHI Chunhe. Observation on the curative effect of recombinant bFGF eye drops in the treatment of dry eye[J]. Journal of Jiangsu University (Medicine Edition), 2004, 14(4): 287-288. (in Chinese)
15 黄彩虹, 刘祖国, 张明昌, 等. 重组牛bFGF凝胶治疗中度干眼的多中心随机双盲平行对照临床试验[J]. 中华眼科杂志, 2021, 57(12): 930-938
HUANG Caihong, LIU Zuguo, ZHANG Mingchang, et al. Efficacy of a recombinant bovine basic fibroblast growth factor gel for the treatment of moderate dry eye: a multicenter randomized double-blind parallel controlled clinical trial[J]. Chinese Journal of Ophthalmology, 2021, 57(12): 930-938. (in Chinese)
16 DEEKSE D, LAMBY N. Cenegermin: a review in neurotrophic keratitis[J]Drugs, 2020, 80( 5): 489-494.
doi: 10.1007/s40265-020-01289-w
17 曾敦征, 张采华, 陈光约, 等. 金因舒滴眼液治疗丝状角膜炎疗效观察[J]. 求医问药, 2013, 11(1): 361
ZENG Dunzheng, ZHANG Caihua, CHEN Guangyue, et al. Observation on the therapeutic effect of Jinyinshu eye drops in the treatment of filamentous keratitis[J]. Seek Medical and Ask the Medicine, 2013, 11(1): 361. (in Chinese)
18 FÖRSTERC G, CURSIEFENC, KRUSEF E. Topical application of EGF for the therapy of persisting corneal erosion under cetuximab treatment[J]Ophthalmologe, 2008, 105( 3): 269-273.
doi: 10.1007/s00347-007-1527-8
19 MOON H S, LI L, YOON H J, et al. Effect of epidermal growth factor ointment on persistent epithelial defects of the cornea[J]. BMC Ophthalmol, 2020, 20(1): 147
20 DE ANDREAM, RAVERAR, GIOIAD, et al.The interferon system: an overview[J]Eur J Paediatric Neurol, 2002, A41-A46.
doi: 10.1053/ejpn.2002.0573
21 朱本虎. 重组人干扰素α1b滴眼液治疗单纯疱疹病毒性角膜炎效果观察[J]. 中国乡村医药, 2014, 21(22): 48-49
ZHU Benhu. Recombinant human interferon α1b eye drops in the treatment of herpes simplex keratitis effect observation[J]. Chinese Journal of Rural Medicine and Pharmacy, 2014, 21(22): 48-49. (in Chinese)
22 万金兰, 康　斌. 重组人干扰素α-2b滴眼液治疗上皮型单纯疱疹病毒性角膜炎[J]. 国际眼科杂志, 2014, 14(2): 276-278
WAN Jinlan, KANG Bin. Treatment of epithelial herpes simplex viral keratitis by recombinant human interferon α-2b eye drops[J]. International Eye Science, 2014, 14(2): 276-278. (in Chinese)
23 GALORA, KARPC L, CHHABRAS, et al.Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study[J]Br J Ophthalmol, 2010, 94( 5): 551-554.
doi: 10.1136/bjo.2008.153197
24 QIANZ, FARDEAUC, CARDOSOJ N, et al.Effect of interferon α2a in cystoid macular edema due to intraocular infection[J]Eur J Ophthalmol, 2015, 25( 5): 431-436.
doi: 10.5301/ejo.5000591
25 贺瑞龙. 重组人白细胞介素-1受体拮抗剂对眼角膜上皮细胞损伤的修复作用研究[J]. 中国实用医刊, 2016, 43(17): 93-95
HE Ruilong. Effect of recombinant human interleukin-1 receptor antagonist on repair of corneal epithelial damage[J]. Chinese Journal of Practical Medicine, 2016, 43(17): 93-95. (in Chinese)
26 FISHERC J. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome[J]JAMA, 1994, 271( 23): 1836-1843.
doi: 10.1001/jama.1994.03510470040032
27 RIVERAC, MONSALVEF, SALASJ, et al.Platelet-rich plasma, plasma rich in growth factors and simvastatin in the regeneration and repair of alveolar bone[J]Exp Ther Med, 2013, 6( 6): 1543-1549.
doi: 10.3892/etm.2013.1327
28 ANITUA E, DE LA SEN-CORCUERA B, ORIVE G, et al. Progress in the use of plasma rich in growth factors in ophthalmology: from ocular surface to ocular fundus[J]. Expert Opin Biol Ther, 2021, 22(1): 31-45
29 中国老年医学学会烧创伤分会. 浓缩血小板制品在创面修复中应用的全国专家共识(2020版)[J]. 中华烧伤杂志, 2020, 36(11): 993-1002
The Burn and Trauma Branch of Chinese Geriatrics Society. National expert consensus on application of enriched platelet products in wound repair (2020 version)[J]. Chinese Journal of Burns, 2020, 36(11): 993-1002. (in Chinese)
30 纪庆明, 杨育晖, 陈　昊, 等. 富血小板血浆辅助前交叉韧带重建治疗的临床疗效分析[J]. 中国修复重建外科杂志, 2017, 31(4): 410-416
JI Qingming, YANG Yuhui, CHEN Hao, et al. Clinical evaluations of anterior cruciate ligament reconstruction with platelet rich plasma[J]. Chinese Journal of Reparative and Reconstructive Surgery, 2017, 31(4): 410-416. (in Chinese)
31 SANCHEZ-AVILAR M, MERAYO-LLOVESJ, RIESTRAA C, et al.Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops[J]Int Ophthalmol, 2018, 38( 3): 1193-1204.
doi: 10.1007/s10792-017-0582-7
32 MURUZABAL F J, DE LA FUENTE M, RIESTRA A C, et al. Effects of autologous serum and plasma rich in growth factors (PRGF-Endoret) eye drops on ocular surface myofibroblast differentiation[J]. Invest Ophthalmol Vis Sci, 2015, 56(7): 734
33 NGE W M, SHIMAD T, CALIASP, et al.Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease[J]Nat Rev Drug Discov, 2006, 5( 2): 123-132.
doi: 10.1038/nrd1955
34 SIVAPRASADS, HYKINP, SAEEDA, et al.Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience[J]Eye, 2010, 24( 5): 793-798.
doi: 10.1038/eye.2009.232
35 SINGERMANL J, MASONSONH, PATELM, et al.Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial[J]Br J Ophthalmol, 2008, 92( 12): 1606-1611.
doi: 10.1136/bjo.2007.132597
36 BOCKF, KÖNIGY, KRUSEF, et al.Bevacizumab (Avastin) eye drops inhibit corneal neovascularization[J]Graefes Arch Clin Exp Ophthalmol, 2008, 246( 2): 281-284.
doi: 10.1007/s00417-007-0684-4
37 李　涛, 郑　志, 郑冰清, 等. 贝伐单抗辅助的23G璃体切割术治疗严重增生性糖尿病视网膜病变的疗效观察[J]. 现代生物医学进展, 2013, 13(23): 4488-4491
LI Tao, ZHENG Zhi, ZHENG Bingqing et al. A therapeutic effect observation of 23G pars plana vitrectomy assistedby bevacizumab for severe proli-ferative diabetic retinopathy[J]. Progress in Modern Biomedicine, 2013, 13(23): 4488-4491. (in Chinese)
38 吴庆伟, 邹桂年, 吴志群, 等. 贝伐单抗治疗视网膜静脉阻塞继发黄斑水肿疗效观察[J]. 深圳中西医结合杂志, 2016, 26(23): 3-5
WU Qingwei, ZOU Guinian, WU Zhiqun, et al. Effect observation of retinal vein occlusion with macular edema treated by Bevacizumab[J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2016, 26(23): 3-5. (in Chinese)
39 DAVID W S. 贝伐单抗在眼科的应用引起争议[J]. 科学观察, 2008, 3(2): 54-55
DAVID W S. The application of bevacizumab in ophthalmology is controversial[J]. Science Focus, 2008, 3(2): 54-55. (in Chinese)
40 AVERYR L, PIERAMICID J, RABENAM D, et al.Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration[J]Ophthalmology, 2006, 113( 3): 363-372.e5.
doi: 10.1016/j.ophtha.2005.11.019
41 HUTTON-SMITHL A, GAFFNEYE A, BYRNEH M, et al.Theoretical insights into the retinal dynamics of vascular endothelial growth factor in patients treated with ranibizumab, based on an ocular pharmacokinetic/pharmacodynamic model[J]Mol Pharm, 2018, 15( 7): 2770-2784.
doi: 10.1021/acs.molpharmaceut.8b00280
42 KOKAMEG T, YEUNGL, LAIJ C. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results[J]Br J Ophthalmol, 2010, 94( 3): 297-301.
doi: 10.1136/bjo.2008.150029
43 高　婧, 刘迪丰, 蔡　林. 雷珠单抗临床应用新进展概述[J]. 中国药师, 2015, 18(3): 479-482
GAO Jing, LIU Difeng, CAI Lin. Recent progress in clinical application of Ranibizumab[J]. China Pharmacist, 2015, 18(3): 479-482. (in Chinese)
44 CIOMBORK K, BERLINJ, CHANE. Aflibercept[J]Clin Cancer Res, 2013, 19( 8): 1920-1925.
doi: 10.1158/1078-0432.CCR-12-2911
45 HEIERJ S, BROWND M, CHONGV, et al.Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration[J]Ophthalmology, 2012, 119( 12): 2537-2548.
doi: 10.1016/j.ophtha.2012.09.006
46 褚梦琪, 沈丽君. 视网膜静脉阻塞继发黄斑水肿的最新治疗进展[J]. 中华实验眼科杂志, 2018, 36(1): 65-69
CHU Mengqi, SHEN Lijun. Advances in the treatment of macular edema secondary to retinal vein occlusion[J]. Chinese Journal Experimental Ophthalmology, 2018, 36(1): 65-69. (in Chinese)
47 COHENM N, HOUSTONS K, JUHNA, et al.Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion[J]Canadian J Ophthalmol, 2016, 51( 5): 342-347.
doi: 10.1016/j.jcjo.2016.02.001
48 KOROBELNIKJ F, DOD V, SCHMIDT-ERFURTHU, et al.Intravitreal aflibercept for diabetic macular edema[J]Ophthalmology, 2014, 121( 11): 2247-2254.
doi: 10.1016/j.ophtha.2014.05.006
49 CAMPOCHIAROP A, CLARKW L, BOYERD S, et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion[J]Ophthalmology, 2015, 122( 3): 538-544.
doi: 10.1016/j.ophtha.2014.08.031
50 SALMANA G, SAIDA M. Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity[J]Ophthalmic Res, 2015, 53( 1): 15-20.
doi: 10.1159/000364809
51 LIX, XUG, WANGY, et al.Safety and efficacy of conbercept in neovascular age-related macular degeneration[J]Ophthalmology, 2014, 121( 9): 1740-1747.
doi: 10.1016/j.ophtha.2014.03.026
52 LIUH, ZHANGX R, XUH C, et al.Effects of VEGF inhibitor conbercept on corneal neovascularization following penetrating keratoplasty in rabbit model[J]Clin Ophthalmol, 2020, 2185-2193.
doi: 10.2147/OPTH.S260302
53 任　韩, 黄东勉, 郭翠玲, 等. 玻璃体腔注射康柏西普对不同OCT分型糖尿病黄斑水肿的疗效观察[J]. 国际眼科杂志, 2019, 19(7): 1166-1169
REN Han, HUANG Dongmian, GUO Cuiling, et al. Curative effect of intravitreal injection of conbercept on macular edema in different types of OCT diabetes mellitus[J]. International Eye Science, 2019, 19(7): 1166-1169. (in Chinese)
54 XIAJ P, WANGS, ZHANGJ S. The anti-inflammatory and anti-oxidative effects of conbercept in treatment of macular edema secondary to retinal vein occlusion[J]Biochem Biophysl Res Commun, 2019, 508( 4): 1264-1270.
doi: 10.1016/j.bbrc.2018.12.049
55 ZHOUY, YANGS, YUANY, et al.Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after Conbercept therapy: a post-hoc analysis[J]Eye, 2020, 34( 3): 523-529.
doi: 10.1038/s41433-019-0516-x
56 NGUYENQ D, DASA, DOD V, et al.Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration[J]Ophthalmology, 2020, 127( 7): 963-976.
doi: 10.1016/j.ophtha.2019.12.031
57 MARKHAMA. Brolucizumab: first approval[J]Drugs, 2019, 79( 18): 1997-2000.
doi: 10.1007/s40265-019-01231-9
58 GARWEGJ G. A randomized, double-masked, multicenter, phase Ⅲ study assessing the efficacy and safety of brolucizumab versus aflibercept in patients with visual impairment due to diabetic macular edema (KITE)[J]Klin Monatsbl Augenheilkd, 2020, 237( 4): 450-453.
doi: 10.1055/a-1101-9126
59 SHARMAA, KUMARN, PARACHURIN, et al.Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world[J]Eye, 2021, 35( 5): 1292-1294.
doi: 10.1038/s41433-020-01227-w
60 WELLS J A, WYKOFF C C, WILLIS J R, et al. Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials[J]. Invest Ophthalmol Vis Sci, 2021, 62(8): 1037
61 LID, XIEK, ZHANGL, et al.Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects[J]Cancer Lett, 2016, 377( 2): 164-173.
doi: 10.1016/j.canlet.2016.04.036
[1] 毛宝杰,王明,万曙. 血小板衍生生长因子及其受体在脑出血中的作用[J]. 浙江大学学报（医学版）, 2022, 51(5): 634-639.
[2] 何颖慧,王志萍. 分子伴侣HSP40/DNAJ蛋白家族及其在神经退行性疾病中的作用[J]. 浙江大学学报（医学版）, 2022, 51(5): 640-646.
[3] 李曼,程倩倩,王效静,杨燕. 恶性肿瘤新靶标PHF5A的研究现状及治疗展望[J]. 浙江大学学报（医学版）, 2022, 51(5): 647-655.
[4] 吴雪青,于捷,谈贝,陈忠. 开窍中药在神经病理性疼痛治疗中的作用研究进展[J]. 浙江大学学报（医学版）, 2022, 51(5): 523-533.
[5] 胡小伟,李琳,龚荧荧,方燕,杨琰,许家栋,储利胜. 补阳还五汤激活PI3K-AKT通路促进氧糖剥夺再灌注损伤的脑微血管内皮细胞血管生成[J]. 浙江大学学报（医学版）, 2022, 51(5): 544-551.
[6] 王晓杰,惠琦,金子,饶凤琴,靳磊,余丙洁,BANDA Joshua,李校堃. 生长因子在眼的发育及眼部疾病调控中的作用[J]. 浙江大学学报（医学版）, 2022, 51(5): 613-625.
[7] 李芸,陈新. T淋巴细胞体外发育方法的研究进展[J]. 浙江大学学报（医学版）, 2022, 51(4): 491-499.
[8] 周璐佳,梁景岩,熊天庆. 间充质干细胞来源的外泌体调节缺血性脑卒中后炎症反应的研究进展[J]. 浙江大学学报（医学版）, 2022, 51(4): 500-506.
[9] 袁伟,张世忠,主鸿鹄. FLT3抑制剂治疗急性髓系白血病患者研究进展[J]. 浙江大学学报（医学版）, 2022, 51(4): 507-514.
[10] 薛初晴,傅君芬. 生长激素以外的促生长疗法研究进展[J]. 浙江大学学报（医学版）, 2022, 51(4): 515-520.
[11] 邹杰林,毛靖,石鑫. 牙髓-牙本质复合体再生的影响因素及其生物学策略[J]. 浙江大学学报（医学版）, 2022, 51(3): 350-361.
[12] 孙萍萍,邹炜. 活细胞RNA成像技术及其在生物医学中应用研究进展[J]. 浙江大学学报（医学版）, 2022, 51(3): 362-372.
[13] 邵玥明,荀静娜,陈军,卢洪洲. 人类免疫缺陷病毒感染早期启动抗逆转录病毒治疗的意义[J]. 浙江大学学报（医学版）, 2022, 51(3): 373-379.
[14] 杨朝森,张晓明. 囊泡转运在肌萎缩侧索硬化中的作用研究进展[J]. 浙江大学学报（医学版）, 2022, 51(3): 380-387.
[15] 刘志超,钱周旸,王英男,王慧明. 程序性坏死在骨关节炎病理机制和治疗中的作用[J]. 浙江大学学报（医学版）, 2022, 51(2): 261-265.